## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1 NI									1					1
1. Name and Address of Reporting Person* WIKLER MATTHEW			2. Issuer Name and Ticker or Trading Symbol Matinas BioPharma Holdings, Inc. [MTNB]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner					
(Last) (First) (Middle) C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH SUITE 302		3. Date of Earliest Transaction (Month/Day/Year) 06/30/2019					-	Office	er (give title belo	ow)	Other (specify	below)		
BEDMINSTER,, NJ 07921		4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of Security (Instr. 3)	Da	te onth/Day/Year)			(Instr. 8)	(.	4. Securities Acquired (A) or Disposed of (Instr. 3, 4 and 5)		of (D)	Beneficial Reported	ant of Securities ally Owned Following I Transaction(s)		\ /	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			(Month/Day/Year)		Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)				
Common Stock	06	5/30/2019			A		8,524	A	\$ 0	129,745			D	
				<i>y</i> 0 w		Persor					ction of inf			1474 (9-02)
			Derivative Secu	ıritie	es Acquire	Persor contain the for	ns who ned in t m displ	this for lays a o	m are curren eficiall	not requ itly valid	uired to res	spond unle	ess	1474 (9-02)
1. Title of Derivative Security (Instr. 3)  Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year	3A. Deemed Execution Dat	Derivative Secu 2.g., puts, calls, 4. Transactic	striction on No. 1 S. A. (()	es Acquire rrants, op	Persor contain the for d, Disp tions, co	ns who ned in t m displ	this for lays a of or Ben ble secur able Date	eficiallrities) 7. Tit Amo Under	not required to the and count of erlying	OMB con 8. Price of	spond unle	of 10. Owner: Form of Derivar Securit Direct or India	11. Natu of Indire f Benefici ive Ownersh (Instr. 4)

### **Reporting Owners**

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
WIKLER MATTHEW C/O MATINAS BIOPHARMA HOLDINGS, INC. 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER,, NJ 07921	X				

## **Signatures**

/s/_Jerome D. Jabbour, attorney-in fact for Matthew Wikler	07/02/2019	
**Signature of Reporting Person	Date	

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On June 30, 2019, the Reporting Person was issued 18,524 shares of common stock par value \$.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.